Taysha Gene Therapies Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $678.66 million
- Book Value:
- Revenue TTM:
- $9.60 million
- Operating Margin TTM:
- Gross Profit TTM:
- $2.50 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Taysha Gene Therapies Inc had its IPO on 2020-09-24 under the ticker symbol TSHA.
The company operates in the Healthcare sector and Biotechnology industry. Taysha Gene Therapies Inc has a staff strength of 65 employees.
Shares of Taysha Gene Therapies Inc opened at $3.45 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.95 - $3.45, and closed at $3.02.
This is a -13.71% slip from the previous day's closing price.
A total volume of 4,805,593 shares were traded at the close of the day’s session.
In the last one week, shares of Taysha Gene Therapies Inc have slipped by -16.8%.
Taysha Gene Therapies Inc's Key Ratios
Taysha Gene Therapies Inc has a market cap of $678.66 million, indicating a price to book ratio of 13.3011 and a price to sales ratio of 0.
In the last 12-months Taysha Gene Therapies Inc’s revenue was $9.60 million with a gross profit of $2.50 million and an EBITDA of $-77633000. The EBITDA ratio measures Taysha Gene Therapies Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Taysha Gene Therapies Inc’s operating margin was -822.1% while its return on assets stood at -44.08% with a return of equity of -745.28%.
In Q2, Taysha Gene Therapies Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Taysha Gene Therapies Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.22 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Taysha Gene Therapies Inc’s profitability.
Taysha Gene Therapies Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.1345. Its price to sales ratio in the trailing 12-months stood at 0.
Taysha Gene Therapies Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $81.54 million
- Total Liabilities
- $50.64 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Taysha Gene Therapies Inc ended 2023 with $81.54 million in total assets and $0 in total liabilities. Its intangible assets were valued at $81.54 million while shareholder equity stood at $-37114000.00.
Taysha Gene Therapies Inc ended 2023 with $6.21 million in deferred long-term liabilities, $50.64 million in other current liabilities, 1000.00 in common stock, $-443661000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $45.08 million and cash and short-term investments were $45.08 million. The company’s total short-term debt was $1,638,000 while long-term debt stood at $38.35 million.
Taysha Gene Therapies Inc’s total current assets stands at $54.12 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $10.77 million and inventory worth $0.
In 2023, Taysha Gene Therapies Inc's operating cash flow was $48000.00 while its capital expenditure stood at $48000.
Comparatively, Taysha Gene Therapies Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Taysha Gene Therapies Inc stock is currently trading at $3.02 per share. It touched a 52-week high of $3.89 and a 52-week low of $3.89. Analysts tracking the stock have a 12-month average target price of $5.72.
Its 50-day moving average was $1.55 and 200-day moving average was $1.29 The short ratio stood at 0.08 indicating a short percent outstanding of 0%.
Around 3933.1% of the company’s stock are held by insiders while 2868.5% are held by institutions.
Frequently Asked Questions About Taysha Gene Therapies Inc
Similar Industry Stocks (Biotechnology)
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.